ABSTRACT: Painful diabetic neuropathy (PDN) is a type of peripheral neuropathic pain that is currently difficult to treat using clinically available analgesics. Recent work suggests a progressive depletion of nitric oxide (NO) in nerve cells may be responsible for the pathobiology of PDN. The nitric oxide donor, 3-methyl-4-furoxancarbaldehyde (PRG150), has been shown to produce dose-dependent analgesia in a rat model of PDN. To gain insight into the mechanism of analgesia, methods to radiolabel PRG150 were developed to assess the in vivo biodistribution in rats. The furoxan ring was labeled with 13 N to follow any nitric oxide release and the 3-methyl substituent was labeled with 11 C to track the metabolite using PET imaging. The in vitro metabolic stability of PRG150 was assessed in rat liver microsomes and compared to in vivo metabolism of the synthesized radiotracers. PET images revealed a higher uptake of 13 N over 11 C radioactivity in the spinal cord. The differences in radioactive uptake could indicate that a NO release in the spinal cord and other components of the somatosensory nervous system may be responsible for the analgesic effects of PRG150 seen in the rat model of PDN.
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ABSTRACT: Painful diabetic neuropathy (PDN) is a type of peripheral neuropathic pain that is currently difficult to treat using clinically available analgesics. Recent work suggests a progressive depletion of nitric oxide (NO) in nerve cells may be responsible for the pathobiology of PDN. The nitric oxide donor, 3-methyl-4-furoxancarbaldehyde (PRG150), has been shown to produce dose-dependent analgesia in a rat model of PDN. To gain insight into the mechanism of analgesia, methods to radiolabel PRG150 were developed to assess the in vivo biodistribution in rats. The furoxan ring was labeled with 13 N to follow any nitric oxide release and the 3-methyl substituent was labeled with 11 C to track the metabolite using PET imaging. The in vitro metabolic stability of PRG150 was assessed in rat liver microsomes and compared to in vivo metabolism of the synthesized radiotracers. PET images revealed a higher uptake of 13 N over 11 C radioactivity in the spinal cord. The differences in radioactive uptake could indicate that a NO release in the spinal cord and other components of the somatosensory nervous system may be responsible for the analgesic effects of PRG150 seen in the rat model of PDN. KEYWORDS: Furoxan, nitric oxide (NO), 3-methyl-4-furoxancarbaldehyde (PRG150), positron emission tomography, biodistribution, metabolic stability N itric oxide (NO) is a well-known in vivo signaling molecule involved in many physiological and pathological processes. 1, 2 Biological synthesis occurs endogenously from Larginine, oxygen, and NADPH by various nitric oxide synthase enzymes. 1 The gaseous nature of NO facilitates its free diffusion across cellular membranes, making it ideal for paracrine and autocrine signaling. 2 However, due to its existence as a gaseous free radical, NO is highly reactive and its in vivo action is restricted to limited areas. The extravascular half-life of NO is estimated at 0.09 to 2 s depending upon the O 2 concentration and the distance between blood vessels. 3 Apart from activating the soluble guanylate cyclase and cyclic guanosine monophosphate (sGC/cGMP) signaling pathways, NO also regulates protein function by two chemical reactions: tyrosine nitration 4 and S-nitrosation, also known as S-nitrosylation. 5 These protein modifications play key roles in maintaining homeostasis in the cardiovascular system, 6 learning and memory formation in the central nervous system, 1 modulation of skeletal muscle contractions, 7 pain and nociception, 8 and also play important roles in tumor biology and in inflammation. 9, 10 Over the past decade, there has been significant research on the development of NO prodrugs to overcome the instability and inconvenient handling of aqueous NO solutions. 2 In particular, furoxans, a class of 5-membered heterocycles, have received significant attention as NO donors due to their wide range of NO-related bioactivities including: cytotoxicity, 11, 12 mutagenicity, 13 central muscle relaxant, 14 monamine oxidase inhibition, 15 and blood pressure lowering activity. 16−18 Pseudoaromatic properties help stabilize the ring against acids, electrophiles, and heat. 19, 20 However, they lack stability toward bases and nucleophiles. 19 In furoxans, literature reports suggest that NO release occurs secondary to an attack by a thiolate at the 3-or 4-position leading to ring opening and elimination of nitrosyl anions. 21−26 Painful diabetic neuropathy (PDN) is a long-term complication of diabetes that is a type of peripheral neuropathic pain notoriously difficult to treat with clinically available analgesic and adjuvant drugs due to lack of efficacy and/or dose-limiting sideeffects. 27 Recent work from the Smith laboratory has shown that the furoxan nitric oxide (NO) donor, PRG150 1 (3-methyl-4-furoxancarbaldehyde), produced potent dose-dependent pain relief in a rat model of PDN. 27, 28 However, information on the metabolic stability and biodistribution of PRG150 is lacking. Hence, the aims of the present study were to assess the in vitro metabolic stability of PRG150 using rat liver microsomes and to utilize PET-CT to assess the biodistribution of PRG150 following administration of single bolus intravenous (IV) and subcutaneous (SC) injection in adult male rats.
In nuclear medicine, positron emission tomography (PET) is a functional imaging technique that can be used to determine concentrations of radioactive tracers in the tissues of living organisms. 29 A tracer is composed of a biologically active molecule containing a short-lived radioactive isotope such as oxygen-15 (2 min), nitrogen-13 (10 min), carbon-11 (20 min), or fluorine-18 (110 min). 30 Using PET technology, biologic pathways can be traced to receptor sites of drug action. Combining a CT scan with a PET scan permits the images to be coregistered, which allows for accurate location of organs or other regions of interest (ROI). The mean activity in the ROI can be normalized using body weight and radioactivity injected to give standardized-uptake-values (SUV = ROI/(radioactivity injected × body weight)). The normalized data in the form of SUVs provides a more accurate comparison between separate imaging experiments. Furthermore, drug metabolites can be easily located by their radioactivity. In general, radiolabeling and subsequent in vivo PET imaging provides a sophisticated noninvasive way to analyze drug action. However, the analysis of nitric oxide releasing furoxans, such as PRG150, presents a unique challenge because if NO release is to be monitored by PET imaging, nitrogen-13 must be used, despite its short half-life (10 min). When working with 13 N, procedures and purification must be rapid to obtain an adequate dose. 31 Fortunately, carbon metabolites can be imaged with longer-lived carbon-11 isotopes. Herein, we report a facile method for labeling and purifying 13 N and 11 C labeled 3-methyl-4-furoxancarbaldehyde. Fruttero et al. described the original synthesis of 3-methyl-4-furoxancarbaldehyde in 1989 and demonstrated by 1 H NMR spectroscopy that the aldehyde was quantitatively hydrated in water. 32 The furoxan molecule was synthesized by reacting crotonaldehyde with nitrous acid. Due to the simplicity of this reaction, we thought a 13 N-radiolabeled version could be feasible if 13 . Unfortunately, 13 NO 3 − could not be used to make furoxans and so it must be reduced to 13 NO 2 − prior to radiotracer synthesis. Quantitative reduction of 13 
NO 3
− to 13 NO 2 − can be achieved using a copperized cadmium reduction column. 33−35 Once the crude cyclotron product is passed through a reduction column and subsequently a basic alumina Sep-Pak, 13 
NO 2
− is trapped on a small quaternary methylammonium (QMA) anion exchange cartridge. Concentrated saline (23.4% w/v; 0.15 mL) effectively eluted 90% of the radioactivity. With 13 NO 2 − in hand, the furoxan was made by heating 13 NO 2 − with crotonaldehyde, acetic acid, and sodium nitrite at 70°C for 7 min. This method was also applied to other alkyl α,β-unsaturated aldehydes (Table 1) .
In general, there was a decrease in radiochemical yield with increasing alkyl chain length, which is likely due to poor solubility under aqueous conditions. Attempts were made using preparative HPLC to purify 13 N radiotracers, but a dose adequate for PET imaging could not be produced. Due to time constraints 
a Assessed by HPLC after radiosynthesis and Sep Pak purification (decay corrected). b Activity in the dose (3 mL) after synthesis (typical synthesis time:
13 N 20 min, 11 C, 60 min). c n is the number of repetitions.
when working with 13 N isotopes, purification was optimized experimentally by pressure transferring the crude reaction mixture through several Sep-Paks in series to produce a radiotracer of high radio and chemical purity (see Supporting Information).
After having optimized the purification procedure, it was hypothesized that a 11 C-labeling procedure could be designed and that the same Sep-Pak purification technique could be utilized, provided that similar conditions could be maintained. We envisioned making a 11 C-protected crotonaldehyde species 7 by using a Suzuki cross coupling reaction with pinacolboron precursor 36 6 and 11 C methyl iodide followed by furoxan ring formation using nitrous acid ( Table 1 ). The necessary 11 C intermediate was made by bubbling methyl iodide into a THF solution containing the precursor, palladium, ligand, and sodium acetate followed by heating for 10 min at 70°C, which was adequate for the in situ conversion to 11 C diethoxy crotonaldehyde 7. After cooling, acetic acid was added, followed by sat. NaNO 2 . The reaction mixture was returned to the heating block for an additional 10 min. After cooling and diluting with water (deionized, 0.5 mL), the crude reaction mixture was pressure-transferred through the same Sep-Pak train used to purify the 13 N-derivative, using water (deionized, 3.25 mL) as eluent.
The synthesized 13 N and 11 C tracers were imaged in adult Sprague-Dawley rats (n = 2). Due to the short half-life of the radiotracers and unique molecule metabolism, it was essential for the animals to be anesthetized (isoflurane) and in the PET scanner prior to tracer administration. Tracers were injected intravenously through a tail vein catheter and dynamically imaged for 60 min. 13 N PRG150 time-SUV plots show major distribution in the cardiovascular system followed by the liver, kidneys, and bladder.
11 C PRG150 images also show major uptake into the liver, kidneys, and bladder. In both cases, the 13 N and 11 C PRG150 radioactivity peaked in the liver at 1.5 min (Figure 1 ). In the kidneys, however, 13 N radioactivity peaked at 2.5 min, while the 11 C PRG150 peaked at 5.5 min. The discrepancy suggests that IV administered PRG150 is releasing NO almost immediately upon injection and that it is cleared quickly. The 11 C metabolite appears to remain in the systemic circulation until the kidneys filter it out shortly after the 13 N metabolites. A comparison of the radioactivity elimination in the spinal cord revealed a higher peak uptake of 13 N at 5.5 min, compared to 11 C in both IV (6.5 min) and SC (17.5 min) administration (Figures 1 and 2 ). In addition, 13 N radioactivity from PRG150 remained in the spinal cord outside of the 60 min PET scan window, while 11 C radioactivity was depleted after 45 min. The differences in radioactive uptake could indicate NO release at multiple levels of the somatosensory nervous system including the dorsal root ganglia and the spinal cord thereby contributing to the analgesic effects of PRG150 in the rat model of PDN 8,37−39 by addressing the underlying depletion of NO bioactivity in this neuropathic pain condition. 26 The analgesic efficacy of PRG150 was assessed in the widely utilized streptozotocin-induced diabetic rat model of PDN following single bolus subcutaneous injection (SC) into the back of the neck. The time of onset of analgesia was 15 min, peak analgesia occurred after 60 min, and the duration of pain relief was ∼3 h after single SC bolus dose administration. 27 To gain insight into the extended period of pain relief produced by single SC bolus doses of PRG150 in a rat model of PDN, 27 11 C PRG150 was administered similarly, into the back of the neck of one adult male Sprague−Dawley rat. Using the radioactivity amount injected and animal weight to normalize PET-CT data to SUVs, the subcutaneous injection site ROI data was plotted and fitted with a biexponential trend line to estimate rates of distribution and elimination with SC administration (Figure 3) ; the in vivo half-lives (t 1/2 ) of SC 11 C PRG150 were found to be 3 min in the distribution phase and 120 min in the elimination phase. The peak radioactive uptake in the spinal cord (17.5 min) correlates well to the onset of analgesia (15 min) seen in the rat model of PDN. 27 Also, there was a 37 min difference of peak radioactivity uptake in the kidneys when comparing IV (5.5 min) to SC administration (42.5 min) of 11 C PRG150. Slow elimination from the injection site and delayed kidney uptake could explain the longer duration of analgesia seen when PRG150 is administered subcutaneously.
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For an in vitro comparison, the metabolic stability of PRG150 was assessed using rat liver microsomes. Specifically, rat liver microsomes (protein concentration, 1.2 mg/mL) were incubated with excess PRG150 (100 μM) at 37°C in the presence of NADPH (1 mM). The percentage of PRG150 remaining in the microsomal incubates at each time of assessment was calculated by comparing the concentration of PRG150 remaining in the incubate at each sampling time, relative to the concentration at each sampling time, relative to the concentration at the start of incubation (0 min) that was arbitrarily assigned a value of 100%. It is important to note that in the control experiments ran in parallel, the concentration of PRG150 did not decrease when NADPH was omitted. The in vitro half-life (t 1/2 ) of PRG150 in rat liver microsomes was 2.4 h and the intrinsic clearance (CL int ) was 5.73 μL/min·mg protein ( Figure 3 ). These in vitro parameter values are in the acceptable range for a novel compound with potential for human use as a novel analgesic to treat PDN.
In summary, to help elucidate the mechanism of analgesia seen in rat models of PDN with PRG150, methods were developed to label the furoxan moiety in two different positions to determine biodistribution in rats. Using 13 NO 2 − , PRG150 and other 3-alkylfuroxancarbaldehydes were labeled using nitrous acid to follow nitric oxide release with PET imaging. For a comparison, a method to synthesize 11 C PRG150 was developed to track the carbon metabolite. A Suzuki cross coupling of the boronate precursor 6 with 11 C methyl iodide furnished 11 C diethoxy crotonaldehyde 7 in situ. Using nitrous acid, 11 C PRG150 could be made in moderate radiochemical yield ( 13 N PRG150 34% and 11 C PRG150 21%) and good specific activity ( 13 N PRG150 0.3 Ci/mmol and 11 C PRG150 220 Ci/mmol). In addition, the 13 N and 11 C tracers could be purified quickly using only Sep-Paks and were subsequently administered to rats. Data from the PET-CT scans show an increase of 13 N radioactivity in the spinal cord compared to 11 C activity, indicating a possible site of action for the analgesic effects of PRG150. Both tracers behave similarly in the heart, liver, kidneys, and bladder. The in vivo and in vitro data suggests PRG150 could potentially be a novel analgesic that could effectively treat painful diabetic neuropathy, a type of neuropathic pain that is difficult to treat. 
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